SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

CTMX

CytomX Therapeutics Inc.
BEARISH
Impact 5/10
Horizonmonths Processed11d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor the January 2027 Varseta-M Phase 1 data update for dose selection and registrational strategy clarity; the cash runway into H2 2028 provides a long development horizon but the lack of near-term revenue catalysts keeps the stock dependent on pipeline milestones.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

CTMX drug pipeline →

Varseta-M

▲ Bullish Named in this press release
Impact
Phase
Phase 1
Time to market
If the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.

Price Chart

Loading chart...

Executive Summary

CytomX reported Q3 2026 revenue of $1.7M, down from $6.0M a year ago due to the completion of the Astellas collaboration, and a net loss of $20.0M ($0.09 per share) versus a $14.2M loss in Q3 2025. The company highlighted FDA Fast Track designation for Varseta-M in colorectal cancer and plans for a Phase 1 data update in January 2027, but the financial results reflect a pre-revenue clinical-stage biotech burning cash with no near-term product revenue.

Key Financial Metrics

EPS
−$0.09
est −$0.07 · -28.6%
Revenue
$1.7M
est $10.4M · -83.8% · -71.7% YoY
Rating
miss

Key Facts

  • Q3 2026 total revenue $1.7M vs $6.0M in Q3 2025, down 72% due to completion of Astellas collaboration performance obligation
  • Net loss $20.0M ($0.09 per share) vs net loss $14.2M ($0.09 per share) in Q3 2025
  • Cash, cash equivalents and investments $348.0M at end of Q3 2026, up from $330.3M at Q2 2026; cash runway into H2 2028
  • R&D expenses $16.5M vs $15.3M in Q3 2025; G&A expenses $8.7M vs $6.4M in Q3 2025
  • FDA Fast Track designation granted for Varseta-M in relapsed/refractory metastatic colorectal cancer
  • Phase 1 monotherapy data update for Varseta-M in mCRC expected January 2027; potential registrational study initiation in H1 2027
  • Phase 1/2 combination study of Varseta-M with chemotherapy in 2L mCRC planned by end of 2026
  • CX-801 Phase 1 in advanced melanoma continues; initial combo data with KEYTRUDA expected H1 2027

Financial Impact

Revenue decline of $4.3M YoY; net loss increased by $5.8M; cash position grew by $17.7M QoQ

revenuenet incomeoperating expensescash

Risk Factors

  • Revenue decline reflects completion of Astellas collaboration; no new partnership revenue visible
  • Operating losses are widening as R&D and G&A costs increase
  • Varseta-M is still in early Phase 1; clinical failure or delay would remove the primary value driver
  • Dilution risk from ongoing share count growth (219M shares vs 165M a year ago)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397134

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026